公司新闻

新元素医药任命胡贤君先生为中国临床副总裁
江苏苏州及美国消息(2024年4月16日)-江苏新元素医药科技有限公司(新元素医药,Atom Bioscience)是一家致力于治疗代谢和抗炎领域疾病的创新药物研发企业,今天宣布胡贤君先生自2024年4月16日起加入新元素医药,担任临床副总裁,他将全面负责中国临床事务。...
Atom Bioscience Receives FDA IND Clearance for Clinical Trial of ABP-745 for Acute Gout
JANUARY 02,  2024 JIANGSU, China–January 2, 2024 –Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical...
Atom Bioscience Raises $83M in a D-Round Financing to Support Global Pivotal Clinical Trials of ABP-671, a New Treatment for Chronic Gout
OCTOBER 16,  2023 JIANGSU, China–October 16, 2023–Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical...
Atom Bioscience Doses First Patient in Phase 2b/3 Clinical Trial of a New Treatment for Chronic Gout
OCTOBER 9,  2023 JIANGSU, China–Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.),...
Fierce Biotech: Atom Bioscience Hopes to Make a big bang with New Gout Awareness Campaign
May 24, 2023       By: Ben Adams   Atom Bioscience wants people to see that gout is more that just...
Practical Pain Management: Gout Myths -- Busted
Gout Myths—Busted It’s more your genes and less your lifestyle, say our experts. Aug 11, 2022   ...
BioSpace: Atom Bioscience Announces Positive Phase 2a Results For Investigational New Drug to Treat Chronic Gout
Published: Mar 21, 2022 Preliminary data suggest Atom’s compound reduces uric acid levels to prevent...
Atom Bioscience Marks Gout Awareness Day by Urging Increased Patient Education on Debilitating Effects of the Chronic Disease
PRESS RELEASE Atom Bioscience Marks Gout Awareness Day by Urging Increased Patient Education on Debilitating...
Atom Bioscience Names UC San Diego Professor Robert Terkeltaub, M.D., to its Scientific Advisory Board
PRESS RELEASE Atom Bioscience Names UC San Diego Professor Robert Terkeltaub, M.D., to its Scientific...
Atom Bioscience Announces Positive Results of Phase 2a China Clinical Trial of Its URAT1 Inhibitor for Chronic Gout
PRESS RELEASE Atom Bioscience Announces Positive Results of Phase 2a China Clinical Trial of Its URAT1...
Atom Bioscience to Present at BIO CEO & Investor Conference on February 6, 2023, at the Marriott Marquis, New York City
PRESS RELEASE Atom Bioscience to Present at BIO CEO & Investor Conference on February 6, 2023, at...
Atom Bioscience Names Stanford University Professor Vibeke Strand, M.D., to its Scientific Advisory Board
PRESS RELEASE Atom Bioscience Names Stanford University Professor Vibeke Strand, M.D., to its Scientific...
Atom Bioscience to Present Final Data from its Positive Phase 2a Clinical Trial in Chronic Gout at American College of Rheumatology Annual Meeting, Nov. 10 – 14, in Philadelphia, PA
PRESS RELEASE Atom Bioscience to Present Final Data from its Positive Phase 2a Clinical Trial in Chronic...
Atom Bioscience Announces Abstract for Its Phase 2a Gout Study Accepted for American College of Rheumatology Annual Meeting, Nov. 10 – 14, in Philadelphia
PRESS RELEASE Atom Bioscience Announces Abstract for Its Phase 2a Gout Study Accepted for American College...
Atom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International Convention, June 13 – 16, 2022, San Diego, CA
PRESS RELEASE Atom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International...
On Gout Awareness Day, Let’s Put the Myths to Rest
PRESS RELEASE On Gout Awareness Day, Let’s Put the Myths to Rest Genetic abnormalities are the real cause...
新元素医药宣布,其治疗慢性痛风创新药ABP-671的2a期临床显示出极佳结果
Gout is genetic disease with a surging patient population worldwide
Atom Bioscience to Present at BIO CEO & Investor Conference on February 14, 2022
Lead drug targets unmet medical need in chronic gout Provides significant serum uric acid reduction in...
Atom Bioscience to Present at Biotech Showcase January 10-12, 2022
Lead drug targets unmet medical need in chronic gout Provides significant efficacy without toxic side...
江苏新元素医药完成超3亿元人民币C轮融资
江苏新元素医药科技有限公司近日完成超3亿元人民币的C轮融资,本轮融资由熙诚金睿和高特佳领投,倚锋资本、元禾控股和乾道集团跟投,原股东凯泰资本、丽珠医药、红杉中国继续追加投资。

行业动态

HCPLive.com: Real-World Study Reveals Poor Disease Control in Adults with Gout
HCPLive.com: Study Explores the Patient Perspective of Gout Remission
HCPLive.com: Patients with Gout More Likely to Experience Stroke, Heart Failure
Docwirenews: Serum Uric Acid Levels in Patients with Gout
AJMC: The Connection Between Gout and CVD Requires Cross-Specialty Collaboration
Docwirenews: Gout Associate with Increased CVD and Heart Failure Risk in Black Population
Renal & Urology News: Hyperuricemia, Gout Increase Heart Failure, Death Risk
Practical Pain Management: How can I get my patients to understand that gout is a chronic disease?
WebMD: The Link Between Gout and Depression - What to Know
Docwirenews: Study Reveals High CVD Risk in Gout Patients
Contemporary OBGYN: Exploring the gender differences of comorbidities in patients with gout
HCP Live: Mortality Risk in Gout Has Persisted for Decades Despite Advances in Care
News-Medical.net: Gout unveiled as surprising culprit in neurodegenerative diseases
Renal & Urology News: Gout Burden Increasing Among Asians in the United States
Healio: Well-controlled serum urate levels in gout result in lower fracture risk
1685519774815
Atom Bioscience reports positive Phase IIa chronic gout therapy trial data
At ABP-671 1mg doses given once daily, 86% of the subjects reached serum uric acid levels that were below...
Kidney Disease Among Top Contributors to Excess Death Risk in Veterans With Gout
US veterans with gout have an excess death risk that is largely attributable to comorbidities, particularly...
Arthritis & Rheumatology: Study Compares Gout Treatments with Different Mechanisms of Action - URAT1 Inhibitor vs Xanthine Oxidase Inhibitor
Arthritis & Rheumatology:Study Compares Gout Treatments with Different Mechanisms of Action – URAT1 Inhibitor vs Xanthine Oxidase Inhibitor
Healthline: How Gout Flare-ups May Increase the Risk of Heart Attack, Stroke
How Gout Flare-ups May Increase the Risk of Heart Attack, Stroke Gout is a type of arthritis caused by...
Physicians Weekly: Urate-Lowering Treatments Compared for Gout